Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Diabetes and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women of any racial background~* Age \>= 40 years and \<= 75 years~* SBP\>= 130 mmHg and \< 140 mmHg or DBP \>= 85 mmHg and \< 90 mmHg, average of screening and randomisation visits (in absence of any antihypertensive medication)~* FG \>=100 mg/dl (5.6 mmol/l) and \< 126 mg/dl (7.0 mmol/l) between screening and randomisation (in absence of any antidiabetic medication)~* Waist circumference \>= 102 cm in men and \>= 88 cm in women.~Exclusion Criteria:~* SBP \>= 140 mmHg or DBP \>= 90 mmHg~* Any antihypertensive, antidiabetic or antiobesity medication at the time of or during the 6 months previous to randomisation~* Any current or previous cardiovascular or renal disease requiring continuous administration of Ds, ßBs, ACEIs, ARBs, CAs, and any other antihypertensive medication~* Any medical condition preventing adherence to lifestyle measures included in the protocol~* Hepatic disease as AST (SGOT) or ALT (SGPT) values equal or greater than two times the upper limit of normal~* Chronic renal dysfunction as serum creatinine \> 2.0 mg/dl~* Any gastrointestinal disorder interfering with drug absorption~* Known allergy or contraindications to ACEIs or ARBs~* Pregnant or lactating women; women in reproductive age not using recognized contraceptive methods~* Malignancy within the last 5 years~* Clinically significant autoimmune disorders~* Drug abuse or alcohol abuse within the last 5 years~* History of noncompliance to medical regimens~* Incapacity or unwillingness to sign the informed consent~* Participation in any investigational clinical trial within the last 3 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Diet, exercise and Enalapril (Type: EXPERIMENTAL): one Enalapril 10mg tablet and one Losartan placebo tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet and one Losartan placebo tablet once daily until the end of the randomized treatment phase. After this one Enalapril placebo tablet and one Losartan placebo tablet once daily for six months.
- Diet, Exercise and Losartan (Type: ACTIVE_COMPARATOR): one Losartan 50mg tablet and one Enalapril placebo tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet and one Enalapril placebo tablet once daily until the end of the randomized treatment phase. After this one Losartan placebo tablet and one Enalapril placebo tablet once daily for six months.
- Diet, exercise and Placebo (Type: PLACEBO_COMPARATOR): one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.

Based on this trial design, predict the completion outcome and termination type (if applicable).